Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
20.-22.01.2022 online: ANIM: NeuroIntensivmediziner diskutieren neue Erkenntnisse zu COVID-19
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
FDA approves first leadless pacemaker to treat heart rhythm disorders
Atlanta, Ga., USA ( April 6, 2016 ) – The U.S. Food and Drug Administration today approved the first pacemaker that does not require the use of wired leads to provide an electrical connection between the pulse-generating device and the heart. While the Micra Transcatheter Pacing System works like other pacemakers to regulate heart rate, the self-contained, inch-long device is implanted directly in the right ventricle chamber of the heart.
Pacemakers are surgically implanted medical devices that generate electrical impulses to treat irregular or stalled heart beats, and nearly 1 million people worldwide are implanted with pacemakers each year. The leads in a traditional single chamber pacemaker run from the pacemaker, implanted under the skin near the collarbone, through a vein directly into the heart’s right ventricle; the leads deliver electric pulses from the generator to the right ventricle and help coordinate timing of the chamber’s contractions. Micra eliminates these leads, which can sometimes malfunction or cause problems when infections develop in the surrounding tissue, requiring a surgical procedure to replace the device.
“As the first leadless pacemaker, Micra offers a new option for patients considering a single chamber pacemaker device, which may help prevent problems associated with the wired leads,” said William Maisel, M.D., M.P.H., acting director of the Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health. Micra is intended for patients with a heart arrhythmia called atrial fibrillation or those who have other dangerous arrhythmias, such as bradycardia-tachycardia syndrome.
The FDA evaluated data from a clinical trial of 719 patients implanted with the Micra device, which found that 98 percent of patients in the trial had adequate heart pacing (known as pacing capture threshold) six months after the device was implanted. Complications occurred in fewer than 7 percent of participants in the clinical trials and included prolonged hospitalizations, blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), heart injury, device dislocation and heart attacks.
Micra is contraindicated for patients who have implanted devices that would interfere with the pacemaker, who are severely obese, or who have an intolerance to materials in the device or the blood thinner heparin. It is also contraindicated for patients with veins that are unable to accommodate the 7.8 millimeter introducer sheath or pacemaker implant.
The Micra device is manufactured by Medtronic, located in Mounds View, Minnesota.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products
Food and Drug Administration, 06.04.2016 (tB).